Success Metrics

Clinical Success Rate
83.5%

Based on 111 completed trials

Completion Rate
83%(111/133)
Active Trials
5(3%)
Results Posted
33%(37 trials)
Terminated
22(13%)

Phase Distribution

Ph not_applicable
14
8%
Ph phase_1
50
30%
Ph phase_2
31
19%
Ph early_phase_1
1
1%
Ph phase_3
1
1%

Phase Distribution

51

Early Stage

31

Mid Stage

1

Late Stage

Phase Distribution97 total trials
Early Phase 1First-in-human
1(1.0%)
Phase 1Safety & dosage
50(51.5%)
Phase 2Efficacy & side effects
31(32.0%)
Phase 3Large-scale testing
1(1.0%)
N/ANon-phased studies
14(14.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.2%

111 of 142 finished

Non-Completion Rate

21.8%

31 ended early

Currently Active

5

trials recruiting

Total Trials

167

all time

Status Distribution
Active(8)
Completed(111)
Terminated(31)
Other(17)

Detailed Status

Completed111
Terminated22
unknown17
Withdrawn9
Recruiting4
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
167
Active
5
Success Rate
83.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.0%)
Phase 150 (51.5%)
Phase 231 (32.0%)
Phase 31 (1.0%)
N/A14 (14.4%)

Trials by Status

withdrawn95%
active_not_recruiting11%
unknown1710%
not_yet_recruiting32%
terminated2213%
completed11166%
recruiting42%

Recent Activity

Clinical Trials (167)

Showing 20 of 167 trialsScroll for more
NCT01795313Phase 1

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Terminated
NCT01199562

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Active Not Recruiting
NCT05582460

Exploring Novel Diagnostic Tools for Periprosthetic Joint Infection

Completed
NCT00805402Not Applicable

Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy

Completed
NCT00812669Phase 2

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Completed
NCT06925958Not Applicable

A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma

Not Yet Recruiting
NCT06696027

AYLo - AutoimmunitY and Loss of y

Recruiting
NCT06460142

Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic

Recruiting
NCT00436254Phase 1

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Completed
NCT00410956Phase 2

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Completed
NCT05819762

Evaluation of ClearLLab LS Screening Panel

Completed
NCT06585124

Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas

Recruiting
NCT06521359

Role of Follicular T Cells in Hashimoto's Thyroiditis

Not Yet Recruiting
NCT03621241

Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes

Recruiting
NCT00382200Phase 1

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed
NCT06352515

T Lymphocyte Subsets in Ulcerative Colitis

Not Yet Recruiting
NCT00520767Phase 2

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Completed
NCT06160115

The Role of NK Cells to Detect Blood Infection in ALL.

Unknown
NCT00611351Phase 2

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Completed
NCT00617799

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

Completed

Drug Details

Intervention Type
OTHER
Total Trials
167